{
    "title": "Bendamustine-induced nephrogenic diabetes insipidus - A case report.",
    "doc_id": "33990157",
    "writer": "Desjardins A",
    "year": "2022",
    "summary": "CASE REPORT: We present a case of partial nephrogenic diabetes insipidus after receiving bendamustine, as part of the BeEAM protocol.Management and outcome: The patient was managed with parenteral fluid administration and intranasal desmopressin before the condition â€¦",
    "abstract": "Introduction:\n        \n      \n      In patients with relapsed or refractory lymphoma, high-dose chemoimmunotherapy with subsequent autologous hematopoietic cell transplantation (HCT) is a standard of care. Bendamustine, an alkylating agent, is used in the BeEAM (bendamustine, etoposide, cytarabine, melphalan) protocol for conditioning therapy before autologous HCT in patients with relapsed or refractory lymphoma who are eligible for transplant. There is no consensus regarding an optimal salvage regimen and the approach varies according to toxicity.\n    \n\n\n          Case report:\n        \n      \n      We present a case of partial nephrogenic diabetes insipidus after receiving bendamustine, as part of the BeEAM protocol.Management and outcome: The patient was managed with parenteral fluid administration and intranasal desmopressin before the condition resolved on its own.\n    \n\n\n          Discussion:\n        \n      \n      We summarize published reports of bendamustine-induced diabetes insipidus.",
    "link": "https://pubmed.ncbi.nlm.nih.gov/33990157/",
    "clean_text": "bendamustine induced nephrogenic diabetes insipidus a case report case report we present a case of partial nephrogenic diabetes insipidus after receiving bendamustine as part of the beeam protocol management and outcome the patient was managed with parenteral fluid administration and intranasal desmopressin before the condition introduction in patients with relapsed or refractory lymphoma high dose chemoimmunotherapy with subsequent autologous hematopoietic cell transplantation hct is a standard of care bendamustine an alkylating agent is used in the beeam bendamustine etoposide cytarabine melphalan protocol for conditioning therapy before autologous hct in patients with relapsed or refractory lymphoma who are eligible for transplant there is no consensus regarding an optimal salvage regimen and the approach varies according to toxicity case report we present a case of partial nephrogenic diabetes insipidus after receiving bendamustine as part of the beeam protocol management and outcome the patient was managed with parenteral fluid administration and intranasal desmopressin before the condition resolved on its own discussion we summarize published reports of bendamustine induced diabetes insipidus"
}